ALKS vs JAZZ · P/E 14, rev $1.56B vs P/E 1988, rev $4.07B
Alkermes Plc (ALKS) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ALKS and JAZZ stock pages for the full models.
Not investment advice.